

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *A Cancer J Clin*. 2021;71(3):209–49.
2. GLOBOCAN 2020. Breast [serial online]. 2020 Des (diunduh 22 Juli 2021). Tersedia dari: <https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-factsheet.pdf>
3. World Health Organization of Tumours Editorial Board. Breast tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.
4. Indra. Peringatan hari kanker sedunia [serial onlinet]. 2020 Mar. Tersedia dari: <https://dinkes.sumbarprov.go.id/details/news/470>
5. Hoda SA, Brogi E, Koerner FC, Rosen PP. Rosen's breast pathology. Edisi ke-4. Philadelphia: Wolters Kluwer; 2014.
6. Desmedt C, Salgado R, Fornili M, Pruneri G, Van Den Eynden G, Zoppoli G, et al. Immune infiltration in invasive lobular breast cancer. *J Natl Cancer Inst*. 2018;110(7):768–76.
7. Tille J-C, Vieira AF, Saint-Martin C, Djerroudi L, Fuhmann L, Bidard F-C, et al. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. *Mod Pathol* [serial online]. 2020 (diunduh 22 Juli 2021); Tersedia dari: <http://dx.doi.org/10.1038/s41379-020-0561-9>
8. Narbe U, Bendahl PO, Grabau D, Rydén L, Ingvar C, Fernö M. Invasive lobular carcinoma of the breast: Long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. *Springerplus*. 2014;3(1):1–11.
9. Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. *Semin Diagn Pathol*. 2010;27(1):49–61.
10. Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer : A review of pathogenesis , diagnosis , management , and future directions of early stage disease. *Semin Oncol*. 2019;46(2):121–32.
11. Yang C, Lei C, Zhang Y, Zhang J, Ji F, Pan W, et al. Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: A Propensity Score Matching Study Based on SEER Database. *Front Oncol*. 2020;10(December):1–10.
12. Chen Z, Yang J, Li S, Lv M, Shen Y, Wang B, et al. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma. *PLoS One*. 2017;12(9):1–17.
13. Reed MA, Kutasovic JR, Lakhani SR, Simpson PT. Invasive lobular carcinoma of the breast: Morphology, biomarkers and 'omics. *Breast Cancer Res*. 2015;17(1):1–11.
14. Philippidou M, Pinder SE. Invasive lobular carcinoma of the breast. *Surg Pathol*. 2012;5(3):545–66.

15. Lien HC, Chen YL, Juang YL, Jeng YM. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast. *Breast Cancer Res Treat.* 2015;150(2):447–55.
16. Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, et al. Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. *Oncologist.* 2021;26(6):e943-53.
17. Christgen M, Bartels S, Radner M, Raap M, Rieger L, Christgen H, et al. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling. *Genes Chromosom Cancer.* 2019;58(3):175–85.
18. Flores-Díaz D, Arce C, Flores-Luna L, Reynoso-Noveron N, Lara-Medina F, Matus JA, et al. Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients. *Breast Cancer Res Treat.* 2019;176(1):243–9.
19. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. *Ann Oncol.* 2015;26(2):259–71.
20. Oner G, Altintas S, Canturk Z, Tjalma W, Van Berckelaer C, Broeckx G, et al. The immunologic aspects in hormone receptor positive breast cancer. *Cancer Treat Res Commun.* 2020;25(August):1–6.
21. Burstein HJ, Curigliano G, Loibl S, Dubsy P, Gnani M, Poortmans P, et al. Estimating the benefits of therapy for early stage breast cancer. *Ann Oncol.* 2019.
22. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *npj Breast Cancer.* 2020;6(1):1–16.
23. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol.* 2014;32(27):2959–66.
24. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. *Ann Oncol.* 2014;25(8):1544–50.
25. Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2– breast cancer. *Breast Cancer Res Treat.* 2020;183(2):347–54.
26. Drosler R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, et al. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. *BMC Cancer.* 2012;12(1):1–10.
27. Ahn SG, Cha YJ, Bae SJ, Yoon C, Lee HW, Jeong J. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. *BMC Cancer.* 2018;18(1):1–9.

28. Rakha EA, El-Sayed M, Menon S, Green AR, Lee AHS, Ellis IO. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. *Breast Cancer Res Treat.* 2008;111:121–7.
29. Weidner N, Cote RJ, Suster S, Weiss LM. *Modern surgical pathology.* Edisi ke-2. Philadelphia: Saunders Elsevier; 2009.
30. Fletcher CDM. *Diagnostic histopathology of tumors.* Edisi ke-4. Philadelphia: Elsevier Saunders; 2011.
31. Kumar V, Abbas AK, Aster JC. *Robbins & Cotran pathologic basis of disease.* Edisi ke-10. Philadelphia: Elsevier; 2021.
32. Shousha S, editor. *Breast pathology problematic Issues.* London: Springer; 2017.
33. Union for International Cancer Control. *TNM classification of malignant tumours.* Edisi ke-8. James B, editor. Oxford: Wiley Blackwell; 2017.
34. Rekhman N, Baine MK, Bishop JA. *Quick reference handbook for surgical pathologists.* Edisi ke-2. New York: Springer; 2019.
35. Limaïem F, Budh DP. *Lobular Breast Carcinoma.* [serial online]. 2021 Maret. Tersedia dari: <https://www.ncbi.nlm.nih.gov/books/NBK554578/>.
36. Wilson N, Ironside A, Diana A, Oikonomidou O. Lobular breast cancer: A review. *Front Oncol.* 2021;10(January):1–13.
37. Dossus L, Benusiglio PR. Lobular breast cancer: Incidence and genetic and non-genetic risk factors. *Breast Cancer Res.* 2015;17(1):1–8.
38. Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, et al. The invasive lobular carcinoma as a prototype luminal A breast cancer: A retrospective cohort study. *BMC Cancer.* 2010;10(1):664–72.
39. O'Malley FP, Pinder SE, Mulligan AM, editors. *Breast pathology.* Edisi ke-2. Philadelphia; 2011.
40. Thomas PA, editor. *Breast cancer and its precursor lesions.* London: Humana Press; 2011.
41. Reed AM, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. *Breast Cancer Res.* 2021;23(1):1–16.
42. Moinfar F. *Essentials of diagnostic breast pathology.* New York: Springer; 2007.
43. Tan PH, Sahin AA. *Atlas of differential diagnosis in breast pathology.* Indianapolis: Springer; 2017.
44. Aydiner A, Igci A, Soran A. *Breast disease.* New York: Springer; 2015.
45. Ellis IO, Carder P, Hales S, Lee AH, Pinder SE, Rakha E, et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. *R Coll Pathol.* 2016;G148(version 2):1–160.
46. Luveta J, Parks RM, Heery DM, Cheung K-L, Johnston SJ. Invasive lobular breast cancer as a distinct disease: Implications for therapeutic strategy. *Oncol Ther.* 2020;8(1):1–11.
47. Vo TN, Meric-Bernstam F, Yi M, Buchholz TA, Ames FC, Kuerer HM, et

- al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. *Am J Surg.* 2006;192(4):552–5.
48. Chagpar AB, Killelea BK, Tsangaris TN, Butler M, Stavris K, Li F, et al. A Randomized, controlled trial of cavity shave margins in breast cancer. *N Engl J Med.* 2015;373(6):503–10.
 49. Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The immunology of hormone receptor positive breast cancer. *Front Immunol.* 2021;12(May):1–22.
 50. Soysal SD, Tzankov A, Muenst SE. Role of the tumor microenvironment in breast cancer. *Pathobiology.* 2015;82:142–52.
 51. Annaratone L, Cascardi E, Vissio E, Sarotto I, Chmielik E, Sapino A, et al. The multifaceted nature of tumor microenvironment in breast carcinomas. *Pathobiology.* 2020;87:125–42.
 52. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes a systematic review. *Clin Rev Educ.* 2016;1–7.
 53. Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res.* 2014;16(5):1–12.
 54. Heppner B, Loibl S, Denkert C. Tumor-infiltrating lymphocytes : A promising biomarker. *Breast Care.* 2016;11:96–100.
 55. Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. *Breast Dis.* 2020;39(2):61–9.
 56. Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. *Adv Protein Chem Struct Biol.* 2019;116:135–70.
 57. Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. *Cancer Lett.* 2015;356(2):231–43.
 58. Hewitt SC, Korach KS. Estrogen receptors: Structure, mechanisms and function. *Rev Endocr Metab Disord.* 2002;3:193–00.
 59. Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G, et al. The dynamic structure of the estrogen receptor. *J Amino Acids.* 2011;2011:1–7.
 60. Segovia-Mendoza M, Morales-Montor J. Immune tumor microenvironment in breast cancer and the participation of estrogens and its receptors into cancer physiopathology. *Front Immunol.* 2019;10(Mar):1–16.
 61. Gao X, Nawaz Z. Progesterone receptors – animal models and cell signaling in breast cancer Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. *Breast Cancer Res.* 2002;4(5):182–6.
 62. Li Z, Wei H, Li S, Wu P, Mao X. The role of progesterone receptors in

- breast cancer. *Drug Des Devel Ther.* 2022;16(January):305–14.
63. Pedroza DA, Subramani R, Lakshmanaswamy R. Classical and non-classical progesterone signaling in breast cancers. *Cancers (Basel).* 2020;12(9):1–16.
 64. Plaveti ND, Kuli A, Vrbanec D. Role of HER2 signaling pathway in breast cancer: Biology, detection and therapeutical implications. *Period Biol.* 2012;114(4):505–10.
 65. Elizalde P V., Russo RIC, Chervo MF, Schillaci R. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. *Endocr Relat Cancer.* 2016;23(12):T243-57.
 66. Furrer D, Paquet C, Jacob S, Diorio C. The Human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive biomarker: Molecular insights into HER2 activation and diagnostic implications. *Cancer Progn [Serial Online].* 2018; Tersedia dari: <http://dx.doi.org/10.5772/intechopen.78271>
 67. Badache A, Gonçalves A. The ErbB2 signaling network as a target for breast cancer therapy. *J Mammary Gland Biol Neoplasia.* 2006;11(1):13–25.
 68. Shokouh TZ, Ezatollah A, Barand P, Yang F. Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: Retrospective-observational analytical study. *Med (United States).* 2015;94(32):1–6.
 69. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: Recommendations from the international Ki67 in breast cancer working group. *J Natl Cancer Inst.* 2011;103(22):1656–64.
 70. Chung YR, Jang MH, Park SY, Gong G, Jung WH, Kwon SY, et al. Interobserver variability of Ki-67 measurement in breast cancer. *J Pathol Transl Med.* 2016;50(2):129–37.
 71. Purwanto H, Handojo D, Haryono SJ, Harahap WA, editor. *Panduan penatalaksanaan kanker payudara.* Jakarta: PERABOI; 2014.
 72. Ryan TP. *Sample size determination and power.* New Jersey: Wiley; 2013.
 73. Uchida S, Kojima T, Sugino T. Clinicopathological features , tumor mutational burden , and tumour infiltrating lymphocyte interplay in ERBB2 -mutated breast cancer : In silico analysis. *Pathol Oncol Res.* 2021;27(April):1–9.
 74. Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. *Mod Pathol.* 2016;29(10):1155–64.
 75. Hida AI, Ohi Y. Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method. *Ann Oncol.* 2015;26(11):2351–8.
 76. Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, et al. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. *Mod Pathol.*

- 2017;30(11):1551–60.
77. Costarelli L, Campagna D, Ascarelli A, Cavaliere F, Colavito MH, Ponzani T, et al. Pleomorphic lobular carcinoma: Is it more similar to a classic lobular cancer or to a high-grade ductal cancer? *Breast Cancer Targets Ther.* 2017;9:581–6.
 78. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol.* 2008;26(18):3006–14.
 79. Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: The prognostic impact of histopathological grade, E-cadherin and molecular subtypes. *Histopathology.* 2015;66(3):409–19.
 80. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. *J Immunother Cancer.* 2016;4(59):1–7.
 81. Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. *BMC Med.* 2015;13(1):1–13.

